Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients

F Grawe, R Ebner, T Geyer, L Beyer, M Winkelmann… - European …, 2023 - Springer
Objectives The recently proposed standardized reporting and data system for somatostatin
receptor (SSTR)–targeted PET/CT SSTR-RADS 1.0 showed promising first results in the …

Optimising radioligand therapy for patients with gastro-entero-pancreatic neuroendocrine tumours: expert opinion from an Italian Multidisciplinary Group

N Fazio, M Falconi, E Foglia, M Bartolomei, A Berruti… - Advances in …, 2024 - Springer
Radioligand therapy (RLT) with lutetium (177Lu) oxodotreotide is an approved therapy in
combination with somatostatin analogues (SSAs) for patients with advanced, well …

Peptide receptor radionuclide therapy targeting the somatostatin receptor: basic principles, clinical applications and optimization strategies

N Ahmadi Bidakhvidi, K Goffin, J Dekervel, K Baete… - Cancers, 2021 - mdpi.com
Simple Summary Peptide receptor radionuclide therapy (PRRT) is a systemic treatment
consisting of the administration of a tumor-targeting radiopharmaceutical into the circulation …

Radionuclide theranostics in neuroendocrine neoplasms: an update

M Di Franco, L Zanoni, E Fortunati, S Fanti… - Current Oncology …, 2024 - Springer
Abstract Purpose of Review This paper aims to address the latest findings in
neuroendocrine tumor (NET) theranostics, focusing on new evidence and future directions of …

Cumulative radiation doses from recurrent PET–CT examinations

M Hosono, M Takenaka, H Monzen… - The British Journal of …, 2021 - academic.oup.com
Positron emission tomography (PET–CT) is an essential imaging modality for the
management of various diseases. Increasing numbers of PET–CT examinations are carried …

Cancer Care by Committee to be Superseded by Personal Physician–Patient Partnership Informed by Artificial Intelligence

JH Turner - Cancer Biotherapy & Radiopharmaceuticals, 2023 - liebertpub.com
Multidisciplinary tumor boards (MTBs) have become the reference standard of cancer
management, founded upon randomized controlled trial (RCT) evidence-based guidelines …

Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study

V Rufini, M Lorusso, F Inzani, T Pasciuto… - European Journal of …, 2022 - Springer
Purpose To correlate somatostatin receptor (SSTR) and proliferative activity profile (SSTR2,
SSTR5, Ki-67) at immunohistochemistry (IHC) with SSTR-PET/CT imaging features in a …

Imaging of Small-Bowel Neuroendocrine Neoplasms: AJR Expert Panel Narrative Review

PJ Navin, EC Ehman, JB Liu… - American Journal of …, 2023 - Am Roentgen Ray Soc
Neuroendocrine neoplasms (NENs) of the small bowel are typically slow-growing lesions
that remain asymptomatic until reaching an advanced stage. Imaging modalities for lesion …

Use and perceived utility of [18F]FDG PET/CT in neuroendocrine neoplasms: A consensus report from the European Neuroendocrine Tumor Society (ENETS) …

V Ambrosini, M Caplin, JP Castaño… - Journal of …, 2024 - Wiley Online Library
Abstract Somatostatin receptor (SST) PET/CT is the gold standard for well‐differentiated
neuroendocrine tumours (NET) imaging. Higher grades of neuroendocrine neoplasms …

Neuroendocrine neoplasms of the small intestine and the appendix—update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of …

T Bednarczuk, A Zemczak, M Bolanowski… - Endokrynologia …, 2022 - journals.viamedica.pl
Updated Polish recommendations for the management of patients with neuroendocrine
neoplasms (NENs) of the small intestine (SINENs) and of the appendix (ANENs) are …